ATC Group: B02BD16 Etranacogene dezaparvovec

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B02BD16 in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B02 Antihemorrhagics
3 B02B Vitamin K and other hemostatics
4 B02BD Blood coagulation factors
5 B02BD16

Active ingredients in B02BD16

Active Ingredient Description
Etranacogene dezaparvovec

Etranacogene dezaparvovec is a gene therapy product designed to introduce a copy of the human Factor IX coding DNA sequence into hepatocytes to address the root cause of the Haemophilia B disease. Etranacogene dezaparvovec partially or completely ameliorates the deficiency of circulating Factor IX procoagulant activity in patients with Haemophilia B.